NL-OMON25911RecruitingNot Applicable
Cytoreductive treatment of dabrafenib combined with trametinib to allow completesurgical resection in patients with BRAF mutated, prior unresectable stage III or IV melanoma
Antoni van Leeuwenhoek ziekenhuis0 sites25 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 25
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- •1.Has provided signed informed consent.
Exclusion Criteria
- •A potential subject who meets any of the following criteria will be excluded from participation in this study:
- •1. Known ocular or primary mucosal melanoma.
Investigators
Similar Trials
Completed
Phase 2
Cytoreductive treatment of dabrafenib combined with trametinib to allow complete surgical resection in patients with BRAF mutated, prior unresectable stage III or IV melanomaskin cancermaligne melanoma10040900NL-OMON38944ederlands Kanker Instituut25
Active, not recruiting
Not Applicable
A trial with patients who have a tumor that is too big to resect via operation, to treat them with systemic treatment to downsize the tumor, so that after 8 weeks the tumor can be resected and the patient is cured.unresectable stage III/IV melanomaMedDRA version: 14.1Level: HLTClassification code 10027156Term: Skin melanomas (excl ocular)System Organ Class: 100000004864EUCTR2013-002616-28-NLKI-AV
Active, not recruiting
Not Applicable
CLOFARABINE/ARA-C TREATMENT COMBINED WITH REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTEMYELOID LEUKEMIA IN PRIMARY TREATMENT FAILURE - SET-RICTo improve the 2 year overall survival in patients with acute myeloid leukaemia (AML) in primary treatment failureEUCTR2009-015176-10-FRCHU de Nantes
Not yet recruiting
Phase 2
Dasatinib treatment combination for fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)chronic lymphocytic leukeniaB cell leukemia10024324NL-OMON37297AMC afdeling hematologie35
Active, not recruiting
Phase 1
A study to test a new drug for treating non-small cell lung cancerAdvanced non-small cell lung cancer and BRAF mutationsMedDRA version: 18.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001161-41-ITGlaxoSmithKline Research and Development Limited100